Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ABIVAX
  6. News
  7. Summary
    ABVX   FR0012333284

ABIVAX

(ABVX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ABIVAX Societe Anonyme : Prices $100 Million Capital Raise to Fund Clinical Programs

07/23/2021 | 06:02am EDT


ę MT Newswires 2021
All news about ABIVAX
09/24GLOBAL MARKETS LIVE : Daimler, GeNeuro, Nike, Thermo Fischer...
09/23ABIVAX : presents first-half 2021 financial resultsáand operations update
EQ
09/23Abivax présente ses résultats semestriels 2021 et -4-
DJ
09/23Abivax présente ses résultats semestriels 2021 et -3-
DJ
09/23Abivax présente ses résultats semestriels 2021 et -2-
DJ
09/23Abivax présente ses résultats semestriels 2021 et fait un point d'avancement sur ses ac..
DJ
09/23PRESS RELEASE : Abivax presents first-half 2021 -3-
DJ
09/23PRESS RELEASE : Abivax presents first-half 2021 -2-
DJ
09/23PRESS RELEASE : Abivax presents first-half 2021 financial results and operations update
DJ
09/15ABIVAX : Nombre d'actions composant le capital social et nombre total de droits de vote au..
DJ
More news
Financials
Sales 2021 99,4 M 116 M 116 M
Net income 2021 8,60 M 10,1 M 10,1 M
Net cash 2021 50,3 M 58,8 M 58,8 M
P/E ratio 2021 39,5x
Yield 2021 -
Capitalization 482 M 564 M 564 M
EV / Sales 2021 4,34x
EV / Sales 2022 633x
Nbr of Employees 27
Free-Float 71,6%
Chart ABIVAX
Duration : Period :
ABIVAX Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIVAX
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 30,70 €
Average target price 58,63 €
Spread / Average Target 91,0%
EPS Revisions
Managers and Directors
Hartmut J. Ehrlich Chief Executive Officer
Didier Blondel Chief Financial Officer & Secretary
Philippe Pouletty Chairman
Didier Scherrer Vice President-Research & Development
Paul Gineste Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
ABIVAX-10.76%588
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
IQVIA HOLDINGS INC.46.01%50 128
CELLTRION, INC.-25.49%31 745
SEAGEN INC.-7.88%29 353